Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-centre, Multinational, Open-labelled, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled on Repaglinide, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime NPH Insulin Versus Twice Daily NPH Insulin

NCT01562561 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT01562561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01562561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-centre, Multinational, Open-labelled, Randomised, Parallel, Controlled Trial in Type 2 Diabetic Subjects Inadequately Controlled on Repaglinide, to Compare the Efficacy and Safety of Repaglinide Combined With Bedtime NPH Insulin Versus Twice Daily NPH Insulin
Lead sponsor
Novo Nordisk A/S
Phase
Phase 3
Overall status
Completed
Start date
June 1, 2001
Completion date
December 20, 2002
Enrollment
213 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2